Fax: (617) 632-2165
Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer
Article first published online: 21 JUL 2006
Copyright © 2006 American Cancer Society
Volume 107, Issue 5, pages 975–981, 1 September 2006
How to Cite
Nakabayashi, M., Xie, W., Regan, M. M., Jackman, D. M., Kantoff, P. W. and Oh, W. K. (2006), Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer, 107: 975–981. doi: 10.1002/cncr.22085
- Issue published online: 21 AUG 2006
- Article first published online: 21 JUL 2006
- Manuscript Accepted: 9 MAY 2006
- Manuscript Revised: 12 APR 2006
- Manuscript Received: 9 FEB 2006
- C. Brendan Noonan Charitable Foundation
- Bing Sound Wong Fund for Prostate Cancer Research
- low dose;
- dose escalation;
- androgen-independent prostate cancer;
- secondary hormonal therapy;
- prostate-specific antigen response
High-dose ketoconazole (HDK) in combination with steroids has been recognized as an effective secondary hormonal therapy in androgen-independent prostate cancer (AIPC). However, HDK causes more severe adverse events than low-dose ketoconazole (LDK). To the authors' knowledge, relatively little is known regarding the efficacy of LDK in AIPC. The efficacy of LDK and of subsequent dose escalation from LDK to HDK was evaluated as secondary hormonal therapy in patients with AIPC.
In a single institution, patients with AIPC treated with LDK (at a dose of 200 mg orally 3 times daily) as secondary hormonal therapy with or without concomitant steroids were retrospectively identified. In addition, patients were identified who received dose escalation to HDK (400 mg orally 3 times daily) after experiencing a rising prostate-specific antigen (PSA) level.
Thirty-nine of 138 eligible patients (28.3%, 95% confidence interval [95% CI], 20.9–36.6%) treated with LDK experienced PSA declines ≥50%. The median time to disease progression or dose escalation on LDK was 3.2 months (range, 0.1+–61 months). Dose escalation to HDK was subsequently performed in 55 patients (39.9%), 7 of whom (12.7%) demonstrated a subsequent PSA decline ≥50%. A longer duration of primary androgen deprivation therapy and total duration of all previous hormonal therapies was associated with a longer time to progression with LDK (P < .05). The most common reversible adverse effect of LDK was NCI Common Toxicity Criteria Grade 1 or 2 fatigue (12.3%).
LDK is associated with a PSA response rate comparable to HDK as secondary hormonal therapy in patients with AIPC, but with less toxicity. Although uncommon, additional durable responses occurred in some patients after dose escalation. Cancer 2006. © 2006 American Cancer Society.